重组生物制药包括抗原,抗体,荷尔蒙,细胞因子,单链变量片段,肽已经被用作疫苗,诊断和治疗。植物分子制药是一个强大的平台,它使用植物作为表达系统来大规模生产简单和复杂的重组生物制药。与其他宿主系统相比,植物系统具有一些优势,例如人源化表达,糖基化,可扩展性,降低人类或动物致病污染物的风险,快速和具有成本效益的生产。尽管有很多优点,重组蛋白在植物系统中的表达受到非人翻译后修饰等因素的阻碍,蛋白质折叠错误,构象变化和不稳定性。人工智能(AI)在生物技术的各个领域和植物分子制药方面发挥着至关重要的作用,通过基于AI的多方法的干预来克服阻碍因素,可以实现产量和稳定性的显着提高。基于植物的重组生物制药生产的当前局限性可以借助合成生物学工具和AI算法在基于植物的聚糖工程中进行蛋白质折叠,稳定性,生存能力,催化活性和细胞器靶向。AI模型,包括但不限于,神经网络,支持向量机,线性回归,高斯过程和回归集合,通过预测训练和实验数据集来设计和验证蛋白质结构,从而优化热稳定性等特性,催化活性,抗体亲和力,和蛋白质折叠。这篇评论的重点是,在蛋白质工程和宿主工程中集成系统工程方法和基于AI的机器学习和深度学习算法,以增加植物系统中的蛋白质生产,以满足不断扩大的治疗市场。
Recombinant biopharmaceuticals including antigens, antibodies, hormones, cytokines, single-chain variable fragments, and peptides have been used as vaccines, diagnostics and therapeutics. Plant molecular pharming is a robust platform that uses plants as an expression system to produce simple and complex recombinant biopharmaceuticals on a large scale. Plant system has several advantages over other host systems such as humanized expression, glycosylation, scalability, reduced risk of human or animal pathogenic contaminants, rapid and cost-effective production. Despite many advantages, the expression of recombinant proteins in plant system is hindered by some factors such as non-human post-translational modifications, protein misfolding, conformation changes and instability. Artificial intelligence (AI) plays a vital role in various fields of biotechnology and in the aspect of plant molecular pharming, a significant increase in yield and stability can be achieved with the intervention of AI-based multi-approach to overcome the hindrance factors. Current limitations of plant-based recombinant biopharmaceutical production can be circumvented with the aid of synthetic biology tools and AI algorithms in plant-based glycan engineering for protein folding, stability, viability, catalytic activity and organelle targeting. The AI models, including but not limited to, neural network, support vector machines, linear regression, Gaussian process and regressor ensemble, work by predicting the training and experimental data sets to design and validate the protein structures thereby optimizing properties such as thermostability, catalytic activity, antibody affinity, and protein folding. This review focuses on, integrating systems engineering approaches and AI-based machine learning and deep learning algorithms in protein engineering and host engineering to augment protein production in plant systems to meet the ever-expanding therapeutics market.